Aarti Drugs unit gets three US FDA Form 483 observations
In short
Aarti Drugs’ subsidiary Pinnacle Life Science got three US FDA Form 483 observations after an inspection of its Baddi plant from November 2 to 6.
The company said none of the observations were about data integrity, and it said there was no financial or operational impact.
What the reporting says
Aarti Drugs’ subsidiary Pinnacle Life Science received three US FDA Form 483 observations after an inspection of its Baddi formulations facility from November 2 to 6. The company said none of the observations related to data integrity and said there was no financial or operational impact. The notice highlights regulatory scrutiny at the plant without any reported disruption to business.
Why it matters
Pinnacle Life Science, a subsidiary of Aarti Drugs, received three US FDA Form 483 observations after an inspection at its Baddi formulations facility in Himachal Pradesh between November 2 and 6. The company said the observations were not related to data integrity and that the issue had no financial or operational impact. The event is a regulatory compliance development for the pharma company, with no reported business disruption.